PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX) has announced the addition of two industry veterans, Dr. Karen Smith and Dr. Luke Walker, to its Board of Directors. This strategic move is aimed at bolstering the company’s capabilities in advancing its oncology pipeline.
Martin Lehr, CEO of Context Therapeutics, expressed confidence in the new board members, stating, “Karen and Luke’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Context at this pivotal stage of our growth.” Dr. Smith, a seasoned leader in drug development, has played a crucial role in bringing several drugs to market across multiple therapeutic areas, including oncology and rare diseases. Her previous leadership roles at Jazz Pharmaceuticals, Allergan, and AstraZeneca showcase her extensive expertise.
Dr. Walker, with over 20 years in clinical development, brings a wealth of experience in oncology drug development. His recent role as Chief Medical Officer at Harpoon Therapeutics and his leadership in the development of Tukysa at Seagen underline his capabilities in the field.
Lehr further highlighted the significance of these appointments, noting, “These additions supplement our ongoing effort to build Context into a leading oncology company and advance potential best-in-class T cell engaging bispecifics.” With these appointments, Context Therapeutics is poised to enhance its strategic direction and accelerate its growth in the oncology sector.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.